Operations vs. Projects: Why the Distinction Matters More Than You Think in Biotech and Pharma

Introduction

In biotech and pharma, the line between "project" and "operation" blurs constantly — and when it does, accountability breaks down, resources get misallocated, and timelines slip in ways that are difficult to diagnose until the structural root cause is identified. Drug development looks linear from the outside: IND filing, Phase I, Phase II, Phase III, NDA submission. But inside that pipeline, organizations are simultaneously running clinical monitoring activities, regulatory maintenance filings, pharmacovigilance surveillance, and GMP quality systems that are not temporary, not unique, and should not be managed like projects. The Project Body of Knowledge (PMBOK) is explicit on the core distinction: a project is a temporary endeavor undertaken to create a unique result, while operations are ongoing, repetitive activities that sustain the organization. These two categories require different governance, different staffing models, and different accountability structures — and in life sciences, confusing one for the other carries real regulatory and financial consequence.

Laboratory workstation showing biotech and pharma research setup

The Distinction in a Drug Development Context

The PMBOK defines a project by three core characteristics: it is temporary, it produces a unique result, and it proceeds through progressive elaboration as details become clearer over time. In biotech and pharma, project work can include identifying a drug candidate, filing an IND application, executing clinical trials, implementing a new CTMS platform, or developing a regulatory submission dossier. Each has a defined scope, a sponsor, a PM, and a point at which the work is complete. Operations, by contrast, are governed by SOPs rather than project plans — GMP batch release, routine pharmacovigilance case processing, post-approval maintenance filings, and continuous QMS oversight are all operational in character. They don't close out; they sustain the organization's ability to function in a regulated environment.

Aspect	Operations	Projects
Duration	Ongoing, continuous	Temporary, defined start and end
Purpose	Maintain and improve existing processes	Create unique products or results
Focus	Efficiency, consistency, compliance	Innovation, development, problem-solving
Team Structure	Stable, functional departments	Cross-functional, dynamic teams
Risk Level	Managed and predictable	Higher uncertainty and risk
Resource Allocation	Steady and routine	Variable and flexible
Success Measurement	Operational KPIs (yield, uptime, quality)	Project milestones, deliverables, outcomes

The gray zone is where real confusion lives in life sciences. Several common work types sit ambiguously between these two categories:

• Long-running clinical trials are a project, but the ongoing patient safety monitoring and site management occurring within them take on the character of operations over time.

  
  

• Regulatory maintenance activities — annual reports, label updates, safety surveillance — are operationally continuous but are frequently staffed and budgeted as temporary project work.

  
  

• GMP manufacturing process improvements sit in both worlds explicitly: the improvement initiative is a project; the manufacturing line it improves is an operation.

  
  

This misclassification is a documented root cause of persistent resourcing confusion in mid-to-large pharma organizations, and it rarely surfaces as a structural diagnosis until a program is already in trouble.

Why It Matters: Resourcing, Governance, and Accountability

The downstream consequences of misclassification fall into three categories. On the resourcing side, projects require temporary allocation of subject matter experts drawn from functions for a defined period. Operations require dedicated, stable staffing — because in a GxP environment, turnover in operational roles disrupts continuity and creates direct compliance exposure. When operational work is treated as a project, organizations borrow team members from other programs rather than assigning dedicated FTEs. Pharmacovigilance is the most common example: safety case processing and aggregate reporting are ongoing regulatory obligations, but organizations without mature operational infrastructure frequently staff them with borrowed project personnel — a model that creates both capacity risk and quality risk as program workloads shift.

The governance and accountability implications follow the same logic. Projects need a sponsor, a charter, a PM, and a formal closure process as outlined in the PMBOK. Operations need process owners, SOPs, CAPA processes, and continuous improvement cycles. Applying project governance to operational work creates compliance friction; applying operational governance to project work creates accountability gaps and silent timeline erosion. Perhaps most consequentially, a project has a defined end — when it closes, accountability formally transfers. Operations have no end, and accountability must be continuous, embedded in functional roles rather than project roles. (link) When a drug candidate transitions from Phase III to commercial launch support, that handoff must be explicit and documented. It is frequently not, and post-approval compliance failures are a recognizable consequence.

Organizational Structure and PM Authority

The organizational structure a company chooses — or defaults into — directly determines the authority a PM can exercise, which shapes the realism of every timeline and resource plan that PM is asked to produce. The PMBOK describes a spectrum of structures, each with distinct implications for life sciences PM.

1. In a functional organization, work is arranged by department and employees report vertically within their discipline. The PM has limited formal authority, and functional VPs control resources and priorities. This structure is common in large, established Big Pharma organizations where deep functional expertise is the core strength, but it creates cross-functional coordination challenges that the PM is expected to solve without the authority to do so. (link) 

2. In a matrix structure — the dominant model in mid-to-large pharma — employees report to both a functional manager and a PM. The PMBOK distinguishes three variants: weak matrix, where PM authority is advisory; balanced matrix, where authority is shared and produces productive tension when it works and accountability conflict when it doesn't; and strong matrix, where the PM holds primary authority over resources and priorities. The strong matrix is less common in life sciences but is found in large CROs and organizations that have deliberately elevated the PM function, where project outcomes take clear priority over functional line management. (link) 

3. In a projectized organization, the PM holds full authority and team members are dedicated to the program with no competing functional hierarchy. This structure is common in early-stage and virtual biotech companies with a single asset, where the entire organization effectively is the project team — lean, cross-functional, and organized around the science. (link) 

   
   

Most real-world organizations are composites, and recognizing which structure applies to which work — and being explicit about it in program governance documents — is itself a core PM competency.

When the Structure Fails: A Phase II Scenario

Consider a scenario that is neither hypothetical nor uncommon. A mid-size biotech is advancing an asset into Phase II across four functional departments: Clinical Operations, Regulatory Affairs, Biostatistics and Data Management, and CMC/Manufacturing. Each function reports to its own VP. A trial manager has been designated, but without a governance charter and without cross-functional authority.

The consequences follow a predictable pattern. Site activation delays because Regulatory Affairs is prioritizing a competing NDA submission — the trial manager cannot escalate there because they have no standing. Clinical supply timelines slip because CMC/Manufacturing is planning a batch campaign without visibility into the enrollment forecast, which lives in Clinical Operations. Biostatistics doesn't receive the finalized protocol until four weeks late because Clinical and Regulatory were iterating on amendments without a cross-functional review mechanism. The cumulative result is a four-month delay to first patient in — not because of the science, but because the program structure never gave anyone the authority to prevent it.

What changes with the right structure is straightforward in principle. A strong matrix or projectized program structure would give the program lead explicit authority to convene cross-functional decisions and hold each function accountable to program-level milestones. A governance charter — endorsed at the executive level — establishes that authority before the trial starts, not after delays have already compounded. The matrix structure, when properly designed and supported by executive leadership, allows for quick response to change and centralization of information across functions — both essential in pharmaceutical R&D where uncertainty is constant and timelines are compressed. (link)

Advocating for the Right Structure from the Start

Choosing the right structure is not a passive organizational decision — it requires active advocacy from the PM, ideally before a single resource is assigned to the program. The first step is classifying the work explicitly. Before staffing anything, ask: is this work temporary and unique, or ongoing and repetitive? If it is a project, define the scope, timeline, sponsor, and governance structure upfront. If it is an operation, define the process owner, SOP framework, and dedicated staffing plan before the work begins. If it is both — which in life sciences it often is — document the explicit boundary between the project component and the operational component in both the program charter and the relevant SOPs. That boundary is not bureaucratic overhead; it is the line that determines who owns accountability when the project team disbands. Once the work is classified, match the authority structure to the program's complexity and regulatory consequence:

• Low complexity, single-function scope: A functional structure is sufficient. A dedicated cross-functional PM is not required.

  
  

• Moderate complexity, two to three functional workstreams: Designate a PM with formal charter authority operating in at least a balanced matrix.

  
  

• High complexity, four or more functional workstreams with regulatory milestones: A strong matrix or projectized structure is required, with PM authority explicitly endorsed at the executive level. A practical rule of thumb: the greater the regulatory consequence of a timeline delay, the more formal authority the PM structure must confer.

  
  

The PMBOK project charter is the instrument that makes this authority real. At minimum, it should define:

• What decisions the PM can make unilaterally versus those requiring functional VP approval

  
  

• How resource conflicts between the program and functional departments will be escalated and resolved

  
  

• Who the executive sponsor is and what their active commitment entails

  
  

That charter must be signed before cross-functional resourcing begins — not drafted after the first missed milestone. Finally, operations readiness must be built into the project plan from initiation. For every deliverable that transitions to an ongoing operational state at project close, the project team should identify the operational owner, the functional home, and the governing SOP before the program launches. The project team's job is to deliver a capability; operations' job is to sustain it. A program that closes without a formal handoff plan between those two functions has transferred the deliverable but not the accountability.

Conclusion

The distinction between projects and operations is not semantic — it is structural, financial, and regulatory. Getting it wrong produces teams without authority, accountability that lives nowhere, and timelines that slip for reasons no one can formally own. The PMBOK provides the definitional and structural framework; biotech and pharma organizations must apply it with specificity to their development stage, pipeline complexity, and regulatory environment. The structure precedes the work — and choosing it deliberately, before the program begins, is always less costly than diagnosing why it failed midway through. At Ganvion Biotech Solutions, we help life sciences organizations make these structural decisions with clarity and intention — whether that means designing a program governance charter for a Phase II asset, defining the project-operations boundary for a GMP manufacturing improvement initiative, or advising on the right organizational model for a newly formed development team. If your organization is standing up a new program and hasn't yet answered who has authority to make cross-functional decisions, that answer is the first deliverable.